Valuation: Immatics N.V.

Market Cap 1.06B 943M 878M 799M 1.5B 102B 1.52B 10.61B 4.13B 51.94B 3.97B 3.88B 167B P/E 2026 *
-3.66x
P/E 2027 * -3.67x
Enterprise Value 770M 687M 640M 583M 1.1B 74.2B 1.11B 7.74B 3.01B 37.87B 2.89B 2.83B 122B EV / Sales 2026 *
16.6x
EV / Sales 2027 * 18.1x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 day+1.84%
1 week-9.06%
Current month-11.96%
1 month-19.14%
3 months-22.31%
6 months-25.31%
Current year-26.38%
1 week 7.4
Extreme 7.4
9.16
1 month 7.4
Extreme 7.4
9.56
Current year 7.4
Extreme 7.4
11.94
1 year 7.4
Extreme 7.4
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14.9
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 31/12/2018
Director of Finance/CFO 57 30/09/2025
Chief Tech/Sci/R&D Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 51 30/06/2020
Chairman 70 30/09/2012
Director/Board Member 72 30/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
18/03/26 Other

Chief Financial Officer

350,000 0.2611%
18/03/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-9.06%-17.77%-20.47% 1.06B
+4.16%+3.42%+49.37%+94.17% 74.31B
-0.37%-3.81%+19.75%+78.12% 56.95B
+1.63%-1.61%+3.83%+36.89% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.24%+7.94%+37.50%+32.15% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.63%-1.04%+47.31%+113.72% 39.46B
Weighted average by Cap. +1.75%-0.48%+58.20%+136.72%

Financials

2026 *2027 *
Net sales 46.54M 41.52M 38.68M 35.2M 66.29M 4.48B 66.78M 467M 182M 2.29B 175M 171M 7.35B 39.58M 35.31M 32.9M 29.94M 56.38M 3.81B 56.8M 398M 155M 1.95B 149M 145M 6.25B
Net income -287M -256M -239M -217M -409M -27.68B -412M -2.89B -1.12B -14.13B -1.08B -1.06B -45.41B -310M -276M -257M -234M -441M -29.82B -444M -3.11B -1.21B -15.22B -1.16B -1.14B -48.92B
Net Debt -286M -255M -238M -216M -408M -27.56B -411M -2.87B -1.12B -14.07B -1.07B -1.05B -45.22B -339M -302M -282M -256M -482M -32.62B -486M -3.4B -1.32B -16.65B -1.27B -1.24B -53.51B
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
05/10/26 US$7.730 +1.84% 554,119
02/10/26 US$7.590 -10.07% 1,256,980
01/10/26 US$8.440 -3.87% 639,726
30/09/26 US$8.780 +2.57% 1,898,932
29/09/26 US$8.560 +0.71% 644,378
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.730USD
Average target price
17.63USD
Spread / Average Target
+128.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock